← All trials
NCT05393440
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2022
- Primary completion
- Jul 1, 2023
- Completion date
- Jul 1, 2024
- First posted
- May 26, 2022
- Last posted
- Jun 7, 2022
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen UniversityLead sponsor
- Wuhan UniversityOverall official - principal investigator
- Wuhan UniversityReponsible party - principal investigator
- Wuhan Binhui Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.